Tenth meeting of the Intergovernmental Negotiating Body (INB)
On 16 July 2024, IFPMA delivered a statement at the tenth meeting of the Intergovernmental Negotiating Body (INB) in Geneva, Switzerland.
IFPMA strongly supports the development of a balanced and effective Pandemic Agreement that addresses the needs of all parties. We support the INB objectives and remain committed to contributing constructively to the process. To ensure a robust and effective agreement, the inclusion of the private sector is critical.
The biopharmaceutical industry clearly demonstrated its willingness and ability to rapidly develop and scale up diagnostics, vaccines, and therapies, on a voluntary basis during the COVID-19 pandemic. To further harness the strengths of the industry, and better prepare our global community for the next pandemic, future INB meetings should include formal consultation with industry experts.
Improved modalities for stakeholder inclusion, emphasizing transparency and engagement, will enhance the breadth of expertise contributing to the agreement. This will facilitate the creation of a practical and equitable framework for pandemic preparedness and response.
IFPMA remains steadfast in its commitment to collaborate with the INB, advocating for measures to improve equity, a workable Access-Benefit-Sharing scheme, and a system that incentivizes innovation.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
